Blockbuster ipilimumab decision looms at FDA; Shire's Firazyr gets PDUFA date;

@FierceBiotech: Takeda looks to Deborah Dunsire to guide oncology work. Report | Follow @FierceBiotech 

> The FDA's deadline for making a decision on ipilimumab, Bristol-Myers Squibb's blockbuster new antibody for melanoma, is looming, Late last year the agency pushed back the PDUFA date on ipilimumab to March 26. BMS landed the drug, which analysts estimate could earn upwards of $1.5 billion a year, when it acquired Medarex. Story

> Regulators at the FDA say that data on Oxigene's thyroid cancer drug may clinical activity but it will need to conduct a new study focused on survival benefits in order to win an approval. Oxigene's shares surged seven percent on the news. Report

> Shire says that the FDA has marked August 25th on the calendar as the PDUFA date for Firazyr, a treatment for hereditary angioedema. Story

> Anacor Pharmaceuticals has inked a loan agreement led by Oxford Finance Corporation and partnered with Horizon Technology Finance Corporation for up to $30 million. Release

Pharma News

@FiercePharma: Pfizer exec outlines spin-off strategy. News | Follow @FiercePharma

> Witty: GSK to buck trend of pulling out of UK. Report

> Novartis wins EU nod for presumed MS blockbuster Gilenya. News

> Senators demand FTC probe of KV's Makena pricing. Article

> California joins kickbacks suit against BMS. Item

> Pharma needs to jettison sales-based bonus pay, firm says. Report

> J&J chief hopes missing drugs return by year's end. Story

Biotech IT News

> Medidata financials strong despite NCI contract termination. Article

> Oracle targets subject recruitment at hospitals. Story

> FDA hard-to-search files hold drug safety clues. Report

> MS Sharepoint portals get digital signatures. News

> CRO device automates cardiac trial monitoring. Item

> Survey: Data tracking complexity on the rise. Report

Medical Device News

> Oxford Finance, GE Capital give $20M senior credit facility to NeoVista. Story 

> Medtronic CFO: No shift away from GPOs. Article 

> BridgePoint taps Harrington as CEO. News 

> Stryker CEO sees big bonus in 2010. Report

> Given Imaging gets win in patent fight. Item 

> Zimmer scores government contract. News 

> CardioNexus gets FDA ok for cardiac ultrasound system. Story 

And Finally... A new review suggests that people who regularly take painkillers like ibuprofen may have a lower risk of bladder cancer. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.